SUBSCRIBE
SUBSCRIBE
News   Business

Antibody Developer Symphogen A/S Raises $25 Million Series D

January 12, 2006 | 
1 min read
1/12/2006 – With its treatment for a bleeding disorder moving into Phase I clinical trials, antibody specialist Symphogen A/S has closed a $25 million (EUR20.7 million) Series D round. [ full story ]
Startups Europe
MORE ON THIS TOPIC
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
CAR T therapy developer Autolus laying off 13% of workforce
April 30, 2026
 · 
47 min read
 · 
BioSpace Editorial Staff
IPO Initial Public Offering finance business concept. 3D render vector illustration of Trading on IPO Initial Public Offering, Business Startup and Stock Market Concept. Public offering share launch
IPO tracker
Avalyn beats expectations with $300M debut
April 30, 2026
 · 
11 min read
 · 
Editorial Team
Cost cutting, budget slashing, financial control. Trendy halftone collage. Concept of cost cutting, expense management, and business strategy. Vector illustration
Earnings
Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth
April 30, 2026
 · 
2 min read
 · 
Annalee Armstrong
Pruning tree branches. Gloved hands hold a branch and cutting shears, the gardener takes care of the park. Vector illustration.
Pipeline
AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio
April 30, 2026
 · 
2 min read
 · 
Tristan Manalac